Complement factor H: A biomarker for progression of cutaneous squamous cell carcinoma

Journal of Investigative Dermatology

Volumn 134, Issue 2, 2014, Pages 498-506

  Riihilä, Pilvi M ^a,b   Nissinen, Liisa M ^a,b   Ala Aho, Risto ^a,b   Kallajoki, Markku ^a   Grénman, Reidar ^a   Meri, Seppo ^c   Peltonen, Sirkku ^a   Peltonen, Juha ^d   Kähäri, Veli Matti ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; FACTOR H LIKE PROTEIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA IN SITU; CELL MIGRATION; CELL PROLIFERATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRACELLULAR SIGNALING; INVASIVE CARCINOMA; KERATINOCYTE; MIDDLE AGED; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN CARCINOMA; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; BOWEN'S DISEASE; CARCINOMA, SQUAMOUS CELL; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT FACTOR H; DISEASE PROGRESSION; EPIDERMIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINOCYTES; KERATOSIS, ACTINIC; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PRIMARY CELL CULTURE; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84892779768     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.346     Document Type: Article

References (36)

1. Ajona D, Castano Z, Garayoa M et al. (2004) Expression of complement factor H by lung cancer cells: Effects on the activation of the alternative pathway of complement. Cancer Res 64:6310-8
2. Ajona D, Hsu YF, Corrales L et al. (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178:5991-8
3. Boukamp P, Petrussevska RT, Breitkreutz D et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-71
4. Boukamp P, Stanbridge EJ, Foo DY et al. (1990) c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 50:2840-7
5. Cheng ZZ, Corey MJ, Parepalo M et al. (2005) Complement factor H as a marker for detection of bladder cancer. Clin Chem 51:856-63
6. de Córdoba SR, de Jorge EG (2008) Translational mini-review series on complement factor H: Genetics and disease associations of human complement factor. Clin Exp Immunol 151:1-13
7. Coussens L, Werb Z (2002) Inflammation and cancer. Nature 420:860-7
8. Dovezenski N, Billetta R, Gigli I (1992) Expression and localization of proteins of the complement system in human skin. J Clin Invest 90:2000-12
9. Farshchian M, Kivisaari A, Ala-Aho R et al. (2011) Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 179:1110-9
10. Fedarko NS, Fohr B, Robey PG et al. (2000) Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complementmediated attack. J Biol Chem 275:16666-72
11. Fedarko NS, Jain A, Karadag A et al. (2004) Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 18:734-6
12. Gorter A, Meri S (1999) Immune evasion of tumor cells using membranebound complement regulatory proteins. Immunol Today 20:576-82
13. Hellwage J, Kuhn S, Zipfel PF (1997) The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor H, displays cell-Attachment activity. Biochem J 326:321-7
14. Johansson N, Ala-Aho R, Uitto V et al. (2000) Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-Activated protein kinase. J Cell Sci 113:227-35
15. Junnikkala S, Jokiranta TS, Friese MA et al. (2000) Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 164:6075-81
16. Junnikkala S, Hakulinen J, Jarva H et al. (2002) Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 87:1119-27
17. Junttila MR, Ala-Aho R, Jokilehto T et al. (2007) p38a and p38d mitogenactivated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26:5267-79
18. Kivisaari AK, Kallajoki M, Ala-Aho R et al. (2010) Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol 163:726-35
19. Kivisaari AK, Kallajoki M, Mirtti T et al. (2008) Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-Associated squamous cell carcinomas. Br J Dermatol 158:778-85
20. Kononen J, Bubendorf L, Kallioniemi A et al. (1998) Tissue microarrays for high-Throughput molecular profiling of tumor specimens. Nat Med 4: 844-7
21. Losse J, Zipfel PF, Józsi M (2010) Factor H and factor H-related protein 1 bind to human neutrophils via complement receptor 3, mediate attachment to Candida albicans, and enhance neutrophil antimicrobial activity. J Immunol 184:912-21
22. Madan V, Lear JT, Szeimies RM (2010) Non-melanoma skin cancer. Lancet 375:673-85
23. Mueller MM, Peter W, Mappes M et al. (2001) Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 159:1567-79
24. Ratushny V, Gober MD, Hick R et al. (2012) From keratinocyte to cancer: The pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122:464-72
25. Ricklin D, Hajishengallis G, Yang K et al. (2010) Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11:785-97
26. Rogers HW, Weinstock MA, Harris AR et al. (2010) Incidence estimate of nonmelanoma skin cancer in the United States. Arch Dermatol 146:283-7
27. Rutkowski MJ, Sughrue ME, Kane AJ et al. (2010) The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res 59:897-905
28. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9:671-5
29. Schulze M, Pruchno CJ, Burns M et al. (1993) Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 142:179-87
30. Stokes A, Joutsa J, Ala-Aho R et al. (2010) Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 16:2022-35
31. Timar KK, Dallos A, Kiss M et al. (2007) Expression of terminal complement components by human keratinocytes. Mol Immunol 44:2578-86
32. Timar KK, Pasch MC, van den Bosch NH et al. (2006) Human keratinocytes produce the complement inhibitor factor H: Synthesis is regulated by interferon-g. Mol Immunol 43:317-25
33. Toriseva M, Ala-Aho R, Peltonen S et al. (2012) Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells. PLoS One 7:e33041
34. Wilczek E, Rzepko R, Nowis D et al. (2008) The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer 122:2030-7
35. Zipfel PF, Skerka C (1999) FHL-1/reconectin: A human complement and immune regulator with cell-Adhesive function. Immunol Today 20:135-40
36. Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729-40